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Abstract
Background: Over the last years, the mean age of subjects with HIV infection and AIDS is
increasing. Moreover, some epidemiological and clinical differences between younger and older
HIV-infected individuals have been observed. However, since introduction of HAART therapy,
there are controversial results regarding their response to HAART. The aim of the present study
is to evaluate epidemiological and clinical features, response to HAART, and survival in elderly HIV-
infected patients with regard to younger HIV-infected patients.
Methods: A prospective cohort study (1998–2003) was performed on patients from Sabadell
Hospital, in Northeast of Spain. The cohort includes newly attended HIV-infected patients since
January 1, 1998. For the purpose of this analysis, data was censured at December 31, 2003. Taking
into account age at time of diagnosis, it was considered 36 HIV-positive people aged 50 years or
more (Group 1, G1) and 419 HIV-positive people aged 13–40 years (Group 2, G2). Epidemiological,
clinical, biological and therapy data are recorded. Statistical analysis was performed using Chi-
squared test and Fisher exact test, Mann-Whitney U test, Kaplan-Meier, Log Rank test, and Two-
Way ANOVA from random factors.
Results: G1 showed higher proportion of men than G2. The most common risk factors in G1
were heterosexual transmission (P = 0.01) and having sex with men or women (P < 0.001). G1 and
G2 show parallel profiles through the time regarding immunological response (P = 0.989) and
virological response (P = 0.074). However, older people showed lower CD4 cell counts at first
clinic visit (P < 0.001) and, eventually, they did not achieve the same counts as G2. G1 presented
faster progression to AIDS (P < 0.001) and shorter survival (P < 0.001).
Conclusion: Older patients have different epidemiological features. Their immunological and
virological responses are good. However, older patients do not achieve the same CD4 cell counts
likely due to they have lower counts at first clinic visit. Thus, it is essential physicians know older
HIV-infected patients features to consider the possibility of HIV infection in these patients with the
aim of treatment would not be delayed.
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Background
Over the last years, the proportion of old individuals
infected with HIV is increasing. For instance, patients
older than 50 years were more than 10 % of AIDS notifi-
cations made in the last ten years in USA [1]. More than
90 500 individuals over 50 years are living with AIDS in
this country [2]. In Europe, 12.6 % of AIDS patients were
older than 50 years in 1998, whereas 14.5 % of them had
more than 50 years in 2002 [3]. Since the beginning of the
HIV pandemic to 2005, 71 039 cases of AIDS have been
reported in Spain. Mean age at time of diagnosis was 40.3
years [4].
The progressive increase of mean age of subjects with HIV
infection and AIDS could be explained by different fac-
tors. Since 1996, when highly active antiretroviral therapy
(HAART) was available, the history of HIV infection has
evolved from acute or subacute disease to a chronic and
controllable infection. Thus, HIV-infected people grow
older and live longer. Antimicrobial therapy and chemo-
prophylaxis have also allowed the increase survival of
people living with HIV infection. Moreover, some epide-
miological features have changed. The importance of sex-
ual transmission as mode of HIV spread is increasing [1].
Therefore, there are a number of patients who are not
aware of their infection, delaying the diagnosis.
There are epidemiological differences between younger
and older HIV-infected individuals. Older people have a
higher prevalence of sexual HIV transmission, a reduction
of transmission due to intravenous use, and a higher pro-
portion of men [5,6]. On the other hand, there are contro-
versial data about the virological and immunological
responses to HAART as well as survival in older patients.
Some studies indicates that the duration of survival is sig-
nificantly shorter for elderly people due to deficiencies in
the immune system related to age [7,8]. However, others
studies seem to show older people have the same response
to HAART than younger patients [9,10].
In the past, there was little attention to older people with
HIV infection due to the little number of them. Neverthe-
less, the importance of knowledge about the HIV infec-
tion in this population is increasing. The aim of the
present study is to characterize the ways in which older
HIV infected people differ from younger, in a Spanish
cohort. Our previously hypothesis are: firstly, older
patients have different epidemiological and clinical fea-
tures; secondly, they response to HAART in the same way
that younger patients. The survey takes into account epi-
demiological and clinical features, virological and immu-
nological responses, prognostic, and survival.
Methods
Study setting
Subjects were enrolled at the Sabadell Hospital. This is a
765-bed general teaching hospital located in Barcelona,
Spain. It provides primary and specialty care for HIV infec-
tion to 850 patients, approximately.
Design
A prospective cohort study (1998–2003)
Database
Eligible patients were enrolled at the PISCIS project. The
latter is a multicenter cohort (10 hospitals of Catalonia
and one from Balearic Islands) of HIV-infected people
whose features are entered into a computerized database
[11]. Inclusion criteria are: to be more than 16 years old,
to have confirmed positive serology against HIV, and to be
attended at first time from January 1, 1998 in one hospital
of the study. All patients with these conditions are
included in PISCIS cohort independently of AIDS criteria.
Characteristics at first clinic visit are recorded for all
patients by clinicians. Epidemiological, clinical, biologi-
cal and antiretroviral therapy data are sent to the Coordi-
nation Centre every four months. Patients' names were
codified to attain anonymity. The project was conducted
under the terms of Ethics committee approval from
Sabadell Hospital.
Study population
Five hundreds twelve subjects from Sabadell's Hospital
included in the PISCIS project were analyzed. They were
enrolled between January 1, 1998, and December 31,
2003. Two groups were defined taking into account the
age at the time of diagnosis. Patients were included in two
age groups. Group 1 (G1) consisted of HIV-infected peo-
ple 50 years or older (n = 36), whereas Group 2 (G2) con-
sisted of patients aged 13 – 40 years (n = 419). Like other
studies [9,10,12-15]], patients aged between G1 and G2
groups (n = 57) were excluded in order to separate both
groups. It was decided that the cut off would be 50 years
old considering many previously HIV-infection studies
data as well as most significant immunological change
take place around this age.
Parameters evaluated
For each subject enrolled, the following data were
obtained: age, gender, HIV-risk behavior, data of the first
available HIV test, CDC stage of HIV infection, date of
AIDS diagnosis, number of visits, cause of visit, number of
hospitalizations after HIV diagnosis, antiretroviral ther-
apy, AIDS-defining diseases, and data of death. Data col-
lected from laboratory were: number of CD4+ and CD8+
T cells, and HIV RNA viral load with a limit of detection
below 200 copies/ml. Subjects underwent periodical clin-
ical evaluations including laboratory determinations.BMC Infectious Diseases 2006, 6:159 http://www.biomedcentral.com/1471-2334/6/159
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AIDS criteria were established by Centers for Disease Con-
trol and Prevention (CDC), category C.
Statistical analysis
Software program SPSS 11.5 (SPSS Inc, Chicago IL) was
used.
Group comparisons were performed using Chi-squared
test. However, if a cell of the table had few expected cases
(< 5), Fisher exact test was used.
In baseline characteristics analysis, P-values were adjusted
by Bonferroni procedure in order to control the family-
wise Type I error-rate because thirteen simultaneous
hypotheses were tested.
All continuous variables were compared by Mann-Whit-
ney U test because their distributions were not normal.
Kaplan-Meier and Log Rank test were used to estimate and
to compare survival functions between two groups.
The mean increase in the CD4 cell count and the mean
decrease in viral load over time were studied using a
mixed ANOVA procedure. Two-Way ANOVA from ran-
dom factors were used where age group, and time were
fixed factors, and patient was random factor. This model
studies effect of age, time and interaction between age and
time, on CD4 cell count or viral load. Residuals independ-
ency and normality were verified.
Patients were recorded as alive at their last visit. A P < 0.05
was considered significant.
Results
Study population
A total of 512, who were newly attended in our hospital
since January 1, 1998, to December 31, 2003, were ana-
lyzed. They have been diagnosed of HIV-infection since
1983 to 2003. The mean age of HIV patients at first diag-
nosis is progressively rising: 23.34 ± 4.33 years (14 – 33
years) at 1983 – 1988 period, 26.32 ± 4.73 years (16 – 36
years) at 1989 – 1993 period, 31.45 ± 9.04 years (15 – 69
years) at 1994 – 1998 period, and 37.27 ± 14.25 years (17
– 82 years) at 1999 – 2003 period. There were no HIV-
infected people being 50 years or older at the time of diag-
nosis until 1996, when the first old patient was enrolled
(Fig 1).
Characteristics at first clinic visit
A total of 36 subjects belonged to G1 (7.9 %) and 419
individuals to G2 (92.1 %). Their characteristics at first
clinic visit are shown (Table 1). The mean age was 62.44
± 9.57 years (50 – 82 years) for the older group and 28.29
± 6.15 years (14 – 40 years) for the younger group. Older
group showed higher proportion of men than younger
group.
The most common risk behavior for the acquisition of
HIV infection in G1 was sexual contact, whereas injection
drug use was the most important risk factor in G2. More-
over, there were a greater percentage of older patients
whose risk behavior is unknown.
At the enrollment, there was no statistically significant dif-
ference between both groups with regard to the AIDS cri-
teria. However, time from diagnosis of HIV to enrollment
was lower in elderly group (P  < 0.001). In fact, seven
patients from G1 presented AIDS criteria at the enroll-
ment and their mean time since diagnosis of HIV was 6.57
± 11.93 days (0 – 30 days). Fifty patients from G2 were
enrolled with AIDS criteria and their mean time since
diagnosis of HIV was 2273.72 ± 2217.03 days (0 – 7376
days).
In the younger group, there were more individuals with
previous treatment than in older group (P < 0.001).
At first clinic visit, elderly group had a lower mean CD4
cells count [180.83 ± 230.85 (5–1309) cells/mm3 versus
366.89 ± 294.52 (2–1819) cells/mm3,], and a higher viral
load [4.51 ± 1.18 (2.3–5.88) log10 copies/mL versus 4.05
± 1.22 (1.59–5.97) log10 copies/mL]. There were not dif-
ferences relating to CD8 cells count.
There was higher percentage of younger people who had
antibodies against hepatitis C virus (P < 0.001).
Elderly group had higher number of patients who were
admitted to the hospital (47.2 % versus 30.1 %, P  =
0.032). Most elderly patients were admitted to the hospi-
tal because of Pneumocystis jiroveci infection (41.2 %),
tuberculosis (11.8 %), Herpes zoster infection (5.9 %), and
Kaposi's sarcoma (5.9 %). On the other hand, young
patients were admitted to the hospital because of widely
conditions as Pneumocystis jiroveci infection (12 %), tuber-
culosis (9.6 %), bacterial pneumonia (8 %), hepatic dis-
eases, renal diseases, cardiovascular diseases,
encephalopathy, or different kind of infectious diseases.
Treatment
At the enrollment, there was more percentage of younger
patients who received previous treatment. Nevertheless,
most patients from both age groups were treated during
follow-up. In fact, 31 (86.1 %) of individuals being 50
years or older and 338 (80.7 %) of individuals aged 13–
40 years received at least one antiretroviral drug for some
time during follow-up. Number of patients from G1 and
G2 who were receiving treatment at one, two, three, and
four years of follow-up were 23/23 (100%) versus 148/BMC Infectious Diseases 2006, 6:159 http://www.biomedcentral.com/1471-2334/6/159
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164 (90.2%), 17/17 (100%) versus 111/119 (93.3%), 13/
13 (100%) versus 71/75 (94.7%), and 8/8 (100%) versus
46/50 (92%), respectively. There were no statistically sig-
nificant differences between groups at any point of time.
Whereas there was no difference in the use of antiretrovi-
ral, the mean time between HIV diagnosis and therapy ini-
tiation is lower in elderly group [3.48 ± 6.35 (0–24.01)
months versus 73.11 ± 64.15 (0–240.13) months]. Most
of patients received three antiretrovirals (70.9 % in G1
and 61.6 % in G2).
Immune and virological responses
CD4 cell counts and viral load were obtained every six
months during the follow-up since first visit. Figure 2
shows the mean data from CD4 cell counts and viral load
according to time and age group. The mixed ANOVA pro-
cedure was carried out in order to study if both age groups
showed similar virological and immunological responses.
Patients from G1 had higher viral load and lower CD4 cell
count at the enrollment. In both groups, greatest immune
and virological responses were observed in the first six
month. However, these patients did not achieve the same
CD4 cell counts than younger individuals.
Considering increase of CD4+ cell number, both age
group showed parallel profiles (age group × time: P  =
0.989). Statistically significant increase through the time
was observed in both groups (time: P = 0.005). Younger
patients had higher number of CD4+ cells during follow-
up (age group: P < 0.001).
Evolution of HIV diagnosed cases considering age groups Figure 1
Evolution of HIV diagnosed cases considering age groups.BMC Infectious Diseases 2006, 6:159 http://www.biomedcentral.com/1471-2334/6/159
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Taking into account decrease in plasma viral load, both
age groups show not different behavior (age group × time:
P = 0.074). A statistically significant decrease through the
time was observed in both groups (time: P < 0.001), and
older patients had lower viral load (age group: P = 0.013),
since 6 months of follow-up.
Clinical progression
Even if there were no significant difference regarding AIDS
criteria at the enrollment, greater number of older patients
developed AIDS. Of patients without AIDS criteria at
enrollment, percentage of cases and mean time of progres-
sion to first AIDS event were calculated. In fact, 18 (50 %)
cases occurred in G1, and 121 (28.87 %) in G2 (P  =
0.006) during follow-up. Compared by Log Rank test, G1
progression to AIDS was higher than G2 (P < 0.001). In a
Kaplan-Meier analysis, mean times of progression to AIDS
were 57.72 ± 8.91 (40.26 – 75.18) months in G1 and
180.04 ± 5.10 (170.05 – 190.03) months in G2. Younger
HIV-infected people had a probability of remaining AIDS-
free of 96.36 % and 94.32% at one and two years of HIV
diagnosis, respectively. However, older individuals' prob-
abilities were 62.96 % and 58.77 % at the same moments.
The most common AIDS-defining diseases are Pneumo-
cystis jiroveci infection (25 % vs. 9.3 %), tuberculosis (8.3
% vs. 14.31 %), Kaposi's sarcoma (5.5 % vs. 0.23 %), Can-
didiasis (5.5 % vs. 2.38 %), Cytomegalovirus infection (2.7
% vs. 0.47 %), caquexia (2.7 % vs. 0.23 %), Herpes simple
infection (2.7 % vs. 0.23 %), and encephalopathy (2.7 %
vs. 1.19 %). There are significant statistically differences
regarding Pneumocystis jiroveci infection (P = 0.008) and
Kaposi's sarcoma (P = 0.017). There were no differences
between both groups with regard to time since HIV diag-
nosis to Pneumocystis jiroveci infection. There was no statis-
tical difference between age groups with reference to
number of tuberculosis cases. In a Kaplan-Meier analysis,
time of progression to tuberculosis was 6.29 ± 0.53 (5.24
– 7.33) in G1 and 16.05 ± 0.42 (15.23 – 16.86) months
(Log Rank test, P = 0.037). Patients developed one (82.6
%), two (16.7 %) or three (0.7 %) AIDS-defining diseases
at same time. However, there was no significant difference
between both age groups.
Survival
A total of 16 (3.8 %) patients aged 13–40 years were exi-
tus. In contrast, five (13.9 %) of HIV-infected patients
Table 1: Characteristics of the Sample and its Subgroups at first clinic visit
Characteristic Total Sample Group 1 (G1) Group 2 (G2) P-value ¶
Sample size (n) 455 36 419
Sex: n (%)
Male 334(73.4) 33 (91.7) 301 (71.8) 0.127
Female 121(26.6) 3 (8.3) 118 (28.2)
HIV risk factor: n (%)
IDU * 285(62.9) 2 (5.7) 283 (67.7) < 0.001
Heterosexual 123(27) 16 (44.4) 107 (25.5) 0.132
MSM ** 23(5.1) 4 (11.1) 19 (4.5) < 0.999 ||
MSMW ‡ 8(1.8) 6 (16.7) 2 (0.5) < 0.001 ||
Unknown 16(3.5) 8 (22.2) 8 (2) < 0.001 ||
AIDS criteria: n (%)
Yes § 57(12.5) 7 (19.4) 50 (11.9) < 0.999 ||
No 398(87.5) 29 (80.6) 369 (88.1)
Previous treatment: n (%)
Yes 181(39.8) 2 (5.6) 179 (42.7) < 0.001
No 274(60.2) 34 (94.4) 240 (57.3)
CD4 (n° cel./mm3) 352.08 ± 294.10 180.83 ± 230.85 366.90 ± 294.52 < 0.001
CD8 (n° cel./mm3) 957.82 ± 597.10 963.38 ± 733.22 956.97 ± 583.73 < 0.999
Plasma viral load (log10) 4.09 ± 1.22 4.51 ± 1.18 4.05 ± 1.22 0.451
HBsAg #: n (%)
Positive 24(8.1) 1 (4.5) 23 (8.3) < 0.999
Negative 274(91.9) 21 (95.5) 253 (91.7)
Anti-HCV: n (%)
Positive 197(56.8) 3 (13.6) 194 (65.1) < 0.001
Negative 123(43.2) 19 (86.4) 104 (34.9)
¶ P value adjusted by Bonferroni procedure; * IDU: Injection drug user; ** MSM: Men who have sex with men; || Fisher exact test; ‡ MSMW: Men 
who have sex with men or women; § AIDS criteria: Centers for Disease Control and Prevention (CDC) category C; # HBsAg: Hepatitis B 
superficial antigenBMC Infectious Diseases 2006, 6:159 http://www.biomedcentral.com/1471-2334/6/159
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CD4 cell count and viral load (mean ± SD) at first visit and each six months of follow-up Figure 2
CD4 cell count and viral load (mean ± SD) at first visit and each six months of follow-up.
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being 50 years or older died during the follow-up (P =
0.019). Mean survival time was 2520.6 ± 166.2 (2194.8 –
2846.3) months in G1 and 7343.8 ± 79.9 (7186.9 –
7500.5) months in G2. In figure 3, Kaplan-Meier survival
curves are showed. Log Rank test was statistically signifi-
cant (P < 0.001). Every death in the older group occurred
in the first year since HIV diagnosis. Cumulative propor-
tions of younger patients who survived were 99.52 % at
one year, 98.28 % at three years, and 97.40 % at five years.
Discussion
Since 1996, when HAART became widely available, eld-
erly patients infected with HIV are a growing population
[3,6]. HAART is effective in increasing CD4 cell counts
and in decreasing the virus load, so it has been associated
with a 50% decrease in morbidity and mortality with
AIDS. Therefore, HIV-infected individuals have prolonged
survival and they enjoy good life conditions for longer [6].
Besides, the proportion of new infected patients being
older 50 years is increasing. In fact, the mean age at the
time of diagnosis is increasing in our cohort.
There are epidemiological differences associated with age.
Like other surveys [2,5,6,16], older patients in our cohort
have a higher prevalence of sexual HIV transmission, a
lower risk of transmission due to intravenous use, and a
greater proportion of men. Remarkably, the number of
older individuals whose risk behavior was unknown was
much higher than the number of younger patients.
Unlike old patients, younger ones had higher prevalence
of antibodies against Hepatitis C virus. This fact could be
due to injected drugs are an important mode of Hepatitis
C spread, besides infection drug user is the most prevalent
HIV risk factor in younger individuals.
Even though there was more percentage of younger
patients who received previous treatment at enrollment,
most patients from both age groups received treatment
during follow-up. In fact, there were no statistically signif-
icant differences between groups at any point of time con-
sidering number of patients receiving therapy. Besides,
there was no difference in the use of antiretroviral therapy
as described in other studies [10,17]. However, after HIV-
infection diagnosis, older patients initiated HAART ther-
apy sooner probably due to they are diagnosed later. Inter-
estingly, some studies also described that younger and
older patients present the same tolerance to therapy
[1,18]. Thus, further studies should be necessary to ana-
lyze this fact in our region.
Both age groups show increasing CD4 cell counts and
decreasing plasma viral load during follow-up. Like
Grabar et al. observations [5], greatest responses were
observed in the first six month. Virological response is
good in elderly group and they achieve lower viral load.
Previous studies showed younger age is associated with
lower virological response and virological rebounds
[5,12,19,20], probably due to older patients demon-
strated better medication adherence. At least 90–95% of
adherence is required to achieve optimal treatment [21].
Moreover, an inadequate adherence are also associated
with the developed of drug-resistant HIV strains [22] Even
though some studies show older age is associated to better
adherence [21,23,24], other ones observed that lower
virological response in younger age persisted after adjust-
ing for regimen adherence, antiretroviral therapy and dis-
ease stage [12,20]. Therefore, others variables could be
implied. Adherence information was not surveyed in our
database.
The age has been associated to deficiencies in the immune
system, with a progressive depletion of lymphocytes
[7,17,25]. Moreover, thymic volume, which decreases
with age, is associated with recovery of CD4 T cells [1,26].
However, Virad et al. showed CD4 recovery in older
patients [13]. Recent data suggest substantial output of
CD4 cells can be maintained in advanced age, even with
less thymic function. Thus, HAART therapy contributes to
immune recovery in older patients, too [10]. At first clinic
visit, CD4 cell counts were lower in our older patients.
However, both age groups had favorable and parallel
immune response. Elderly group did not achieve the same
immune restoration, probably due to their lower baseline
CD4 cell counts.
Cumulative survival rate, according to age group Figure 3
Cumulative survival rate, according to age group.BMC Infectious Diseases 2006, 6:159 http://www.biomedcentral.com/1471-2334/6/159
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Until the introduction of HAART, age was a strong predic-
tor of disease progression and mortality risk [27]. Never-
theless, there are controversial results since 1996. Some
studies show that older patients have poorer immune
response [7,8]. In contrast, some surveys seem to demon-
strate that virological and immune response in older HIV-
infected people receiving HAART is similar to that of
younger patients [9,14,28,29]. For instance, Perez et al.
observed older patients have a great benefit associated
with HAART, suggesting lower survival in older people
was due to late diagnosis [6]. Tumbarello et al. have dem-
onstrated that older patients under HAART therapy can
achieve the same response, although they present a more
severe HIV infection [10]. According to our results, it is felt
that our analysis agrees with the last studies.
There was no significant difference with regard to AIDS
criteria at the enrollment in our patients. Nevertheless,
not only greater number of older patients developed
AIDS, but also disease progression and mortality since
HIV diagnosis were faster in older patients.
Previous data showed that elderly patients are diagnosed
later [30,31]]. Taking into account good immunological
and virological responses were observed in both groups,
faster progression to AIDS and shorter survival in older
patients may be due to delayed diagnosis and thus a
smaller chance of having received antiretrovirals. In fact,
there was lower proportion of elderly patients being on
treatment at enrollment. Moreover, elderly patients had
lower CD4 cell counts at enrollment and thus they did not
achieve the same counts as younger patients at the end of
follow-up. There is not a high HIV-infection suspicious in
old patients' diagnosis because of: firstly, different epide-
miological features associated to age; secondly, the fact
that HIV-infection has been associating to younger age.
Thus, many old people are unaware of their serostatus. In
fact, in our cohort there were a high number of older HIV-
infected patients whose risk behavior is unknown. Conse-
quently, even though older patients' response to HAART is
parallel to younger patients' response, their immune and
virological data were worst at first clinic visit and thus
their progression to AIDS was faster and their survival was
shorter.
Conclusion
In conclusion, there are epidemiological differences
related to age. Immunological and virological behaviors
during follow-up are similar within both age groups.
However, older patients have worse features at first clinic
visit. Consequently, it is essential physicians know older
HIV-infected patients features to consider the possibility
of HIV infection in these patients with the aim of treat-
ment would not be delayed.
Competing interests
MaMercedes Nogueras, Gemma Navarro, Esperança Antón,
Montserrat Sala, Manel Cervantes, MaJosé Amengual: The
authors declare that they have no competing interests.
Ferran Segura: He has participated in scientific meeting
receiving financial support from pharmaceutical industry
regarding antibiotics and antiretrovirals. However, none
of them are concerning this study.
Authors' contributions
MMN carried out the analysis and interpretation of data,
and the preparation and revision of manuscript.
GN participated in the study concept and design, and revi-
sion of manuscript.
EA participated in the acquisition of subjects and epide-
miological and clinical data.
MS participated in the study concept, acquisition of sub-
jects and epidemiological and clinical data.
MC participated in the study concept, acquisition of sub-
jects and epidemiological and clinical data.
MJA participated in the acquisition of data from labora-
tory.
FS participated in the study concept and design, and revi-
sion of manuscript.
Acknowledgements
The authors would like to thank Ángeles Jaén, Jordi Casabona, and PISCIS 
group for their design and collaboration on database.
We thank Jordi Real Gatius and Eva Penelo Werner for advice on biosta-
tistics. We also thank José Manuel Aisa Mancho for reviewing the English.
This study was supported by Fundación Barcelona SIDA 2002, FIPSE 2000-
2002-05-22, and "Red Española de Investigación en Patología Infecciosa" – 
REIPI.
References
1. Manfredi R: HIV infection and advanced age emerging epide-
miological, clinical, and management issues.  Ageing Res Rev
2004, 3:31-54.
2. Centers for Disease Control and Prevention: HIV/AIDS surveillance Vol-
ume 13. Issue 2 Atlanta, GA: Centers for Disease Control and Pre-
vention; 2001. 
3. HIV/AIDS Surveille in Europe. European Centre for the Epi-
demiological Monitoring of AIDS.  Med-year report 2002, n° 67 .
4. Centro Nacional de Epidemiología: Vigilancia Epidemiológica del
SIDA en España.  REGISTRO NACIONAL DE CASOS DE SIDA ACTU-
ALIZACIÓN A 31 DE DICIEMBRE DE 2004 Informe Semestral n° 1, Año
2005.
5. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C,
Mahamat A, Lang JM, Costagliola D: Immunologic and Clinical
Response to Highly Active antiretroviral therapy over 50
years of age. Results from the French Hospital Database on
HIV.  AIDS 2004, 18:2029-2038.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2006, 6:159 http://www.biomedcentral.com/1471-2334/6/159
Page 9 of 9
(page number not for citation purposes)
6. Perez JL, Moore RD: Greater effect of highly active antiretrovi-
ral therapy on survival in people aged ≥ 50 years compared
to younger people in an urban observational cohort.  Clin
Infect Dis 2003, 36:212-218.
7. Kaufmann G, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA:
The extent of HIV-1 related immunodeficiency and age pre-
dict the long term CD4 T lymphocyte response to potent
antiretroviral therapy.  AIDS 2002, 16:359-367.
8. Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S: Decreased
recovery of CD4 lymphocytes in older HIV-infected patients
beginning highly active antiretroviral therapy.  AIDS 2001,
15:1576-1579.
9. Knobel H, Guelar A, Valldecillo G, Carmona A, Gonzalez A, Lopez-
Colomes JL, Saballs P, Gimeno JL, Diez A: Response to highly
antiretroviral therapy in HIV-infected patients aged 60 years
or older alter 24 months follow-up.  AIDS 2001, 15:1591-1593.
10. Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S,
Montuori E, Tamburrini E, Tacconelli E, Cauda R: Older age does
not influence CD4 cell recovery in HIV-1 infected patients
receiving highly active anti retroviral therapy.  BMC Infect Dis
2004, 4:46.
11. Jaén A, Casabona J, Esteve A, Miró JM, Tural C, Ferrer E, Riera M, Seg-
ura F, Force L, Sued O, Vilaró J, Masabeu A, García I, Dorca E, Altès
J, Navarro G, Podzamczer D, Villalonga C, Clotet B, Gatell JM, Grupo
de estudio PISCIS: [Clinical-epidemiological characteristics
and antiretroviral treatment trends in a cohort of HIV
infected patients. The PISCIS Project].  Med Clin (Barc) 2005,
124:525-531.
12. Goodkin K, Shapshak P, Asthana D, Zheng W, Concha M, Wilkie FL,
Molina R, Lee D, Suarez P, Symes S, Khamis I: Older age and
plasma viral load in HIV-1 infection.  AIDS 2004, 18(Suppl
1):87-98.
13. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N,
Bruun JN, Johnson M, Lundgren JD, EuroSIDA Study Group: Influ-
ence of age on CD4 cell recovery in human immunodefi-
ciency virus-infected patients receiving highly active
antiretroviral therapy: evidence from the EuroSIDA study.  J
Infect Dis 2001, 183:1290-1294.
14. Tumbarello M, Rabagliati R, De Gaetano Donati K, Bertagnolio S,
Tamburrini E, Tacconelli E, Cauda R: Older HIV-positive patients
in the era of highly active antiretroviral therapy: changing of
a scenario.  AIDS 2003, 17:128-131.
15. Uphold CR, Maruenda J, Yarandi HN, Sleasman JW, Bender BS: HIV
and older adults clinical outcomes in the era of HAART.  J
Gerontol Nurs 2004, 30:16-24.
16. Suarez-Lozano I, Fajardo JM, Garrido M, Roca B, Garcia-Alcalde ML,
Geijo P, Selma D, Lozano F, Teira R, Viciana P, Perez-Cortes S,
Domingo P, Menchero A, Galindo MJ, Cosin J, Ribera E, Arribas JR,
Lacalle JR: Epidemiological trends of HIV infection in Spain:
preventive plans have to be oriented to new target popula-
tion (Spanish VACH Cohort).  AIDS 2002, 16:2496-2499.
17. Butt AA, Dascomb KK, Desalvo KB, Bazzano L, Kissinger PJ, Szerlip
HM:  Human Immunodeficiency virus infection in elderly
patients.  South Med J 2001, 94:397-400.
18. Adeyemi D, Bradi S, Max B, Chinomona N, Barrer D: HIV infection
in older patients.  Clin Infect Dis 2003, 36:1347.
19. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M,
Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola
D: Factors associated with clinical and virological failure in
patients receiving a triple therapy including a protease inhib-
itor.  AIDS 2000, 14:141-149.
20. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth
L, Cassuto JP, Moatti JP, Raffi F, Leport C, Aproco Study Group: Pre-
dictors of virological rebound in HIV-1-infected patients ini-
tiating a protease inhibitor-containing regimen.  AIDS 2002,
16:21-29.
21. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C,
Wagener MM, Singh N: Adherence to protease inhibitor ther-
apy and outcomes in patients with HIV infection.  Ann Intern
Med 2000, 133:21-30.
22. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Boz-
zette SA: Predictors of self-reported adherence and plasma
HIV concentrations in patients on multidrug antiretroviral
regimens.  J Acquir Immune Defic Syndr 2000, 23:386-395.
23. Wutoh AK, Brown CM, Kumoji EK, Daftary MS, Jones T, Barnes NA,
Powell NJ: Antiretroviral adherence and use of alternative
therapies among older HIV-infected adults.  J Natl Med Assoc
2001, 93:243-250.
24. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam
MN, Stefaniak M: Medication adherence in HIV-infected adults:
effect of patient age, cognitive status, and substance abuse.
AIDS 2004, 18(Suppl 1):19-25.
25. Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lava-
getto G, Casti A, Franceschi C, Passeri M, Sansoni P: Shortage of
circulating naive CD8+ T cells provides new insights on
immunodeficiency in aging.  Blood 2000, 95:2860-2868.
26. Ruiz-Mateos E, Rubio A, Vallejo A, De la Rosa R, Sanchez-Quijano A,
Lissen E, Leal M: Thymic volume is associated independently
with the magnitude of short- and long-term repopulation of
CD4+ T cells in HIV-infected adults after highly active
antiretroviral therapy (HAART).  Clin Exp Immunol 2004,
136:501-506.
27. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD: Importance
of age at infection with HIV-1 for survival development of
AIDS in UK haemophilia population. UK Haemophilia Cen-
tre Directors' Organisation.  The Lancet 1996, 347:1573-1579.
28. Wellons M, Sanders L, Edwards L, Bartlett J, Helad A, Schmader K:
HIV infection: treatment outcomes in older and younger
adults.  J Am Geriatr Soc 2002, 50:603-607.
29. Grimes RM, Otiniano ME, Rodriguez-Barradas MC, Lai D: Clinical
experience with human immunodeficiency virus-infected
older patients in the era of effective antiretroviral therapy.
Clin Infect Dis 2002, 34:1530-1533.
30. Gordon S, Thompson S: The changing epidemiology of human
immunodeficiency virus infection in older patients.  J Am Ger-
iatr Soc 1995, 43:7-9.
31. Zelenetz P, Epstein M: HIV in the elderly.  AIDS patient Care ST
1998, 4:255-262.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/6/159/pre
pub